T1	Participants 68 102	patients with Parkinson's disease.
T2	Participants 242 269	two groups of patients with
T3	Participants 270 289	Parkinson's disease
T4	Participants 323 334	10 patients
T5	Participants 335 382	with a moderate motor impairment insufficiently
T6	Participants 462 517	eight patients with L-dopa-induced peak-dose dyskinesia
